Clinical Trial Update: Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ceftazidime-avibactam for carbapenem-resistant Enterobacteriaceae infections has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carbapenem-resistant Enterobacteriaceae Infection

Drugs mentioned

• ceftazidime/avibactam (ceftazidime/avibactam)

Snippet

Sponsor: King Faisal Specialist Hospital & Research Center | Conditions: Carbapenem-Resistant Enterobacteriaceae Infection | Phase 3 | Status: TERMINATED